Overall, nusinersen reduces NF-L levels in both the CNS and serum, with the most significant decline occurring in children with the most severe SMA phenotypes [88, 90, 106, 107, 109]. The gene discussed is NEFL; the disease is proximal spinal muscular atrophy.